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Abstract
Hypothyroidism is a common disorder in the United States which is often caused by disease of
the thyroid gland, resulting in inadequate serum thyroxine (T4) and triiodothyronine (T3) levels.
With the use of L-thyroxine, most patients will return to an euthyroid state with cessation of
hypothyroid symptoms. Some, however, will continue to experience hypothyroid symptoms
despite the use of L-thyroxine and normal thyroid hormone levels. The case report presents a 38year-old, Caucasian, female who was diagnosed with hypothyroidism and prescribed
levothyroxine. She was advised to follow-up in four to six weeks following her initial visit to
evaluate the effectiveness of the medication. The clinician may encounter a challenging situation
if, upon follow-up, the patient presents with continued complaint of hypothyroid symptoms, but
normal thyroid hormone levels. Controversy remains on whether to treat those who return with
persistent hypothyroid symptoms with combination therapy (L-thyroxine plus liothyronine). The
literature review will discuss current recommendations on the use of monotherapy versus
combination therapy for hypothyroidism, including the potential risks and benefits of
combination therapy and suggestions for future research.
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Monotherapy versus Combination Therapy in the Treatment of Hypothyroidism: A Case Report
Background
A 38-year-old, Caucasian, female presented to the clinic with complaint of fatigue and
dry skin. Further evaluation of her subjective symptoms revealed she was experiencing irregular
menstrual periods, cold intolerance, and having difficulty losing weight. Her physical exam was
relatively unremarkable, but blood tests revealed her thyroid stimulating hormone (TSH) was
elevated. She was diagnosed with hypothyroidism and prescribed levothyroxine 100mcg by
mouth daily. She was advised to follow-up in four to six weeks to recheck her TSH and free T4
levels.
Hypothyroidism is a common disorder that affects 4.6% of the United States population,
occurring more often in women (Tariq, Wert, Cheriyath, & Joshi, 2018). Hypothyroidism can be
caused by a disruption anywhere in the hypothalamic-pituitary-thyroid pathway but is most often
caused by a disease in the thyroid gland resulting in decreased secretions of T4 and T3 (Ross,
2019). This leads to decreased serum levels of T4 and T3 and, due to compensatory mechanisms,
increased levels of TSH. The altered hormone levels may cause symptoms involving several
organ systems and tissues in the body. Common symptoms of hypothyroidism may include
weight gain, fatigue, neurologic dysfunction, constipation, and dry skin (Surks, 2019).
Most people will return to a euthyroid state, with normal thyroid hormone levels and
cessation of hypothyroid symptoms, with the sole use of levothyroxine, a synthetic version of
T4. However, 5% to 10% of patients will continue to experience hypothyroid symptoms while on
L-thyroxine (LT4) monotherapy despite normal TSH and free T4 levels (Tariq et al., 2018).
There is evidence in the literature that suggests patients with persistent hypothyroid symptoms
should be treated with a combination therapy, consisting of synthetic liothyronine (LT3) in
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addition to LT4. Combination therapy for the treatment of hypothyroidism has been an interest
for many years, but inconsistent evidence remains as to the benefit of the use of combination
therapy (LT4 plus LT3) versus monotherapy (LT4). This case report will review the literature to
further determine the risks and benefits of combination therapy versus monotherapy in the
treatment of hypothyroidism.
Case Report
A 38-year-old, Caucasian, female with no remarkable medical history presented with
complaint of fatigue and abnormally dry skin. She is a reliable historian and provided the
information for the encounter. She stated symptoms of excessive fatigue and dry skin started five
months prior. She noted she drinks one pot of coffee every day to help give her energy and
admitted to inadequate water intake. She denied rashes or pigmentation changes in her skin. In
addition to the fatigue and dry skin, she noted she had been having irregular menstrual periods.
She stated her periods were becoming more frequent and she experienced heavier flows. She
noted her last menstrual period was 22 days prior. She also complained of not being able to lose
weight after having her third child, one year ago. Her current medications include a daily
multivitamin and probiotic with no known allergies. She admitted to a family history of thyroid
dysfunction. She lives at home with her three children and works full-time. She denied use of
tobacco products, drugs or alcohol. Her review of systems revealed she experienced cold
intolerance. She otherwise denied fever and respiratory, gastrointestinal, genitourinary, and
psychological symptoms. Her vital signs on the day of the visit were stable: blood pressure,
130/80, heart rate, 76, temperature, 97.8 ° F, and respirations, 16.
Upon physical exam, she was pleasant, cooperative and in no acute distress. She
exhibited normal mood and affect. Her neck was supple with no adenopathy, thyromegaly or
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palpable thyroid nodules. Her heart rate and rhythm were regular with no discernable murmurs,
rubs or gallops. Lungs were clear to auscultation throughout. Her skin was noted to be dry with
no rashes or unusual moles or lesions. No pallor was noted. She exhibited 2+ patellar deep
tendon reflexes, bilaterally. A complete blood count (CBC), complete metabolic panel (CMP),
TSH level and free T4 level were ordered. The CBC, CMP and free T4 labs were unremarkable
while the TSH was elevated at 6.61mIU/L. She was diagnosed with hypothyroidism and
prescribed levothyroxine 100mcg by mouth daily. Education about hypothyroidism, including
clinical manifestations, was provided. Information about levothyroxine and possible adverse side
effects were discussed. She was advised to decrease caffeine intake and to increase water intake
and to apply lotion for her dry skin. It was recommended that she follow-up in four to six weeks
to check her TSH and free T4 levels and to evaluate symptoms.
Literature Review
The literature is inconsistent with its recommendations for the treatment of
hypothyroidism with monotherapy versus combination therapy. A literature search was
conducted using the CINAHL and PubMed search engines. Search terms included:
"hypothyroidism", "monotherapy", "combination", and " liothyronine". Results were limited to
literature published within the last 5 years and in the United States. The literature search resulted
in a review of 11 articles that explore the topic of combination therapy versus monotherapy for
the treatment of hypothyroidism. The articles included primary and secondary literature, which
consist of original studies, review articles, systematic reviews and practice guidelines. The
literature review will discuss current recommendations for the treatment of hypothyroidism and
will include alternative causes for persistent hypothyroid symptoms, limitations to current
studies, and recommendations for future studies.
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The clinical practice guidelines supported by the American Association of Clinical
Endocrinologists and the American Thyroid Association state those with hypothyroidism should
be treated with LT4 monotherapy because current evidence does not support the use of LT4 and
LT3 combination therapies (Garber et al., 2012). These recommendations are congruent with the
majority of 13 other national practice guidelines published worldwide (Kraut & Farahani, 2015).
The European Thyroid Association and the British Thyroid Association are the only
organizations who have indicated LT3 may be considered for experimental treatment but include
several caveats including the patient must have persistent hypothyroid symptoms, have a normal
TSH for over six months, and other autoimmune conditions must be ruled out (Kraut & Farahani,
2015). In a comprehensive review of several national practice guidelines, the use of combination
therapy was dismissed with several of the organizations not providing supporting evidence for
their recommendations.
The literature included in this review is consistent in its support and recommendation for
the use of levothyroxine monotherapy for treating hypothyroidism, with the exception of one
retrospective study that supports the use of combination therapy and one study that states
combination therapy should not be ruled out as a treatment option (Jonklaas & Burman, 2016;
Tariq et al., 2018). The retrospective study included a chart review of 100 patients being treated
with combination therapy compared to 2400 patients receiving monotherapy. Data was collected
for clinical signs and symptoms which included thyroid hormone levels and responses to a
Medical Outcomes Study Short Form-20 questionnaire (Tariq et al., 2018). The authors state
symptoms of hypothyroidism improved significantly in the group receiving combination therapy
and did not cause hyperthyroidism (Tariq et al., 2018). Based on the collected data, the authors
concluded the addition of LT3 is a safe and effective way to improve quality of life in those with
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persistent hypothyroid symptoms (Tariq et al., 2018). Jonklaas and Burman (2016) have
indicated peaks and troughs of T3 serum levels in their studies when adding LT3 into treatment
regimens which do not replicate the natural serum T3 levels produced by the throid. They
hypothesize the lack of evidence of improving health outcomes using combination therapy may
be caused by the inconsistent T3 levels during therapy (Jonklaas & Burman, 2016). Their
findings suggest that combination therapy cannot be ruled out as a beneficial treatment option
until there have been studies that administer extended release LT3 or at least three times daily
doses (Jonklaas & Burman, 2016).
The literature reviewed was highly consistent with supporting LT4 monotherapy for the
treatment for hypothyroidism (Escobar-Morreale, Botella-Carretero, & Morreale de Escobar,
2015; Foeller & Silver, 2015; Hennessey & Espaillat, 2018; Jonklaas, 2016; Kraut & Farahani,
2015; Linder & Clements, 2015). In addition to the lack of consistent evidence supporting
combination therapy, several articles cited adverse effects of LT3 and provided alternative
causes of persistent hypothyroid symptoms as arguments against the use of combination therapy
(Duntas & Wartofsky, 2016; Escobar-Morreale et al., 2015; Foeller & Silver, 2015; Hennessey
& Espaillat, 2018; McAninch & Bianco, 2016). It has been shown through earlier clinical trials
that LT3 administered at 100 to 175mcg/day can be associated with thyrotoxicosis (McAninch &
Bianco, 2016). Though lowered dosages of LT3 resulted in resolution of symptoms, a trial of
LT4 80mcg combined with LT3 20mcg resulted in symptoms of hyperthyroidism, including
increased palpitations, tremor, perspiration, and anxiety, when compared to high doses of LT4
(McAninch & Bianco, 2016). Combination medications with LT3 dosages as low as 7.5 to
8.5mcg have been associated with the presence of bone-remodeling markers in the urine,
indicating even small doses of LT3 may cause adverse effects (Escobar-Morreale et al., 2015).
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This is important to consider when educating patients about the use of over-the-counter thyroid
supplements. Even though the supplements are under the Food and Drug Administration
supervision, they are likely to contain amounts of T4 and T3 that may increase risk of
hyperthyroidism (Duntas & Wartofsky, 2016). One 17-year-long observation study found no
significant difference in death, cardiovascular disease, arrhythmias, or diabetes in those who
received LT3, though there was an increase in the use of antipsychotic drugs (Hennessey &
Espaillat, 2018). It is advised not to treat hypothyroidism with combination therapy in pregnant
women due to the risks of adverse effects to the fetus. The addition of LT3 causes serum T4
levels to decrease which results in less T4 available for placental transport (Foeller & Silver,
2015). Fetal neurogenesis is dependent on maternal T4 levels, therefore, a reduction in maternal
T4 can put the fetus at risk for delayed intellectual development (Foeller & Silver, 2015).
There are potential alternative causes for persistent hypothyroid symptoms that would not
indicate the initiation of combination therapy. Some symptoms of hypothyroidism, such as
fatigue, cognitive difficulties, and anxiety, can be vague and difficult to measure. Many patients
with these vague symptoms may be screened and diagnosed with subclinical hypothyroidism.
Subclinical hypothyroidism is defined as having an elevated TSH concentration in the presence
of a normal serum T4 concentration (Ross, 2019). Those with subclinical hypothyroidism have a
TSH level <10mIU/L and do not have symptoms of hypothyroidism (Ross, 2019). "In many
cases, this finding prompts the conclusion that the subclinical hypothyroidism is the case of the
nonspecific symptoms, and thyroid hormone therapy is initiated. The patients in whom the
cause-effect was incorrect contribute to the increasing number of euthyroid but symptomatic
patients" (McAninch & Bianco, 2016, p. 53). Two review articles indicate physical,
psychological, social and economic factors that may present with similar symptoms. Examples
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include diabetes mellitus, pernicious anemia, vitamin deficiencies, obesity, stressful life events,
poor sleep habits, depression and anxiety (Hennessey & Espaillat, 2018; Jonklaas, 2017).
Assumption that persistent symptoms are caused by hypothyroidism could lead to a misdiagnosis
of a serious condition.
Although most of the sources recommend the use of LT4 monotherapy to treat
hypothyroidism, several of the articles listed an alternative cause for persistent hypothyroid
symptoms that may indicate the need for the addition of LT3: polymorphisms in the deiodinase
type 2 gene (DIO2). Thyroid hormone, T4, is converted to T3 by deiodinases at the cellular level
in the periphery (Hennessey & Espaillat, 2018). Two single-nucleotide polymorphisms in the
DIO2 have been found which may inhibit the enzyme activity, reducing the ability to convert T4
to T3 (Duntas & Wartofsky, 2016; Hennessey & Espaillat, 2018). Up to 10% to 16% of the
population are homozygous for this polymorphism (Jonklaas, 2017). In a large clinical trial,
those with a known polymorphism of DIO2 reported increased levels of well-being while on
combination therapy (McAninch & Bianco, 2016). Personalized medication, based on genetics,
may have a role in the treatment of hypothyroidism.
There are limitations identified throughout past studies comparing monotherapy to
combination therapy in hypothyroidism. Several studies have limitations that include employing
pre-study LT4 requirements and administering doses of LT3 that were not congruent with the
natural ratios produced by the human thyroid (Linder & Clements, 2015). Several studies were
limited by their small sample size and restrictive inclusion criteria (Jonklaas, 2017; Linder &
Clements, 2015). It is advised for future studies to use standardized outcomes and measures to
validate the effects of quality of life between the two study groups (Jonklaas, 2017). Two review
articles and one original study suggest trialing extended release LT3 or dosages of three times a
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day. Synthetic T3 has a short half-life and once daily, or even twice daily, dosing is not sufficient
to maintain steady levels throughout the body (Duntas & Wartofsky, 2016; Jonklaas, 2016;
Jonklaas & Bianco, 2014). Maintaining a constant level of T3 in all tissues may increase patient
satisfaction and outcomes (Jonklaas, 2016). Though only one article clearly stated a
recommendation for the use of combination therapy for hypothyroidism, several of the other
articles acknowledge the limitations of past studies and the potential for future studies that may
reveal beneficial results for combination therapy.
Learning Points
The following are important learning points that may be concluded from the literature review:
1. Currently, the practice guidelines supported by the American Association of Clinical
Endocrinologists and the American Thyroid Association state to use LT4 monotherapy in
the treatment of hypothyroidism.
2. It is important to educate patients about the possible adverse effects related to the use of
other-the-counter thyroid supplements due to the potential for exceeding average T4 and
T3 levels.
3. Though combination therapy is not recommended, it has become more popular in recent
years and clinicians may encounter more patients with hypothyroidism on a combination
therapy. It is important to discuss the possible risks of combination therapy, especially in
those who are pregnant or who are trying to conceive.
4. Combination therapy may be considered for those with polymorphisms of DIO2.
5. Future randomized controlled studies, with the use of extended release LT3 or three times
a day dosing, is recommended since past studies tested LT3 dosages that produced lower
serum T3 levels then what is naturally produced by the thyroid.
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